Biomime stent is a novel sirolimus-eluting stent (SES) (Meril Life Sciences Pvt. Ltd., Gujarat, India) with an ultra-thin stent platform (65 μm) and a biodegradable polymer licensed for the treatment of de novo coronary lesions. However no data regarding the efficacy and safety of this stent in an "all-comers" patient population treated with percutaneus coronary interventions (PCI) have been published so far. In this registry the investigators aimed to collect clinical and angiographic information about an extensive "all-comers" employ of this novel stent.
Study Type
OBSERVATIONAL
Enrollment
250
percutaneous coronary angioplasty with implantation of at least one Biomime stent
Azienda Ospedaliero Universitaria Maggiore della Carita
Novara, Piedmont, Italy
RECRUITINGtarget vessel revascularization
rate of target vessel percutaneous or surgical reintervention for recurrent symptoms or inducible ischemia at follow up testes
Time frame: 1 year
death from any cause
death from any cause after the procedure
Time frame: 1 year
cardiac death
death form cardiac causes (reinfarction, sudden cardiac death, death during coronary reintervention, heart failure, arrhythmias)
Time frame: 1 year
reinfarction
reinfarction in the myocardial region supplied by the treated coronary artery
Time frame: 1 year
target lesion revascularization
rate of target lesion percutaneous reintervention for recurrent symptoms or inducible ischemia at follow up testes
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.